moneyheap
ATRC · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is AtriCure, Inc. (ATRC) stock moving?
AtriCure's Q3 2026 report on Nov 3 was strong: revenue of $154.5M, up 15%, beat the roughly $151.2M consensus, and adjusted EPS of $0.17 beat estimates. Management raised FY2026 adjusted EPS guidance to $0.40-$0.46 and GAAP EPS guidance to $0.21-$0.27, and narrowed sales guidance to $606M-$610M. Several brokers responded on Nov 4 with Buy or Overweight ratings and price targets of $67-$70. The stock closed at $65.53 that day, up about 8.5% on volume of 1.34M, but it has since given back the entire move. It closed at $56.26 on Nov 10, its lowest close in the 30-day window, below the roughly $59-$62 range it held before results. Volume was heavy on Nov 3, Nov 4 and Nov 9, which points to active repositioning rather than a quiet drift. A $546K insider sale reported Nov 5 is small relative to the company's size and adds little signal. At the Nov 9 UBS conference, management reiterated long-term targets, including an adjusted EBITDA margin above 20%, and outlined sales-territory investments. The current price sits well below the $67-$70 analyst targets, so the gap between fundamentals and the share price is the main question.
News behind the analysis
- AtriCure Management Discusses Strategic Growth and Financial Outlook at UBS Global Healthcare ConferenceManagement updated investors on the EnCompass cardiac ablation system, planned sales-territory investments, and long-term financial targets, including an adjusted EBITDA margin target above 20%.
- AtriCure Insider Stock SaleAn insider sold AtriCure shares worth about $546,260, according to a recent SEC filing.
- Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67Canaccord kept its Buy rating and lifted its price target to $67 after the third-quarter results.
- Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy RatingNeedham raised its price target from $64 to $70 and kept its Buy rating.
- Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70Piper Sandler reiterated its Overweight rating and raised its price target to $70.
- BTIG Raises AtriCure Price Target to $70BTIG kept its Buy rating and raised its price target from $63 to $70.
- AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 ResultsAnalysts lifted price targets to $70 after AtriCure beat Q3 estimates and raised FY2026 EPS and sales guidance.
- AtriCure Reports Third-Quarter 2026 Financial ResultsAtriCure reported Q3 2026 revenue of $154.5 million, up 15%, and net income of $4.1 million.
- AtriCure Q3 Adj. EPS $0.17 Beats $(0.05) Estimate, Sales $154.450M Beat $151.217M EstimateAdjusted EPS of $0.17 and sales of $154.45M both beat consensus estimates for the third quarter.
- AtriCure Raises FY2026 Adj EPS Guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 Est; Raises FY2026 Sales Guidance from $602.000M-$610.000M to $606.000M-$610.000M vs $606.219M EstAtriCure raised FY2026 adjusted EPS guidance to $0.40-$0.46 and narrowed sales guidance to $606M-$610M.
About AtriCure, Inc.
AtriCure, based in Mason, Ohio, makes surgical devices that treat atrial fibrillation (Afib), close off the heart's left atrial appendage, and control pain after surgery. It sells the AtriClip, the most widely sold left atrial appendage device in the world, and its Isolator Synergy system was the first device the FDA approved to treat persistent Afib.
How it makes money
It sells single-use devices to hospitals, mostly through its own sales force in the US and through distributors abroad. Its main product lines are appendage management (AtriClip), open-heart and minimally invasive ablation systems, and cryoSPHERE nerve-freezing probes for post-surgery pain. Pain management is the fastest-growing line. About 83% of revenue comes from the US. Revenue for 2026 is guided at roughly $606–610 million, up about 14%. The company recently started posting small profits.
What usually moves ATRC
- Adoption of AtriClip and ablation in cardiac surgery
- Growth of cryoSPHERE pain management
- Clinical trial readouts (LeAAPS, BoxX-NoAF)
- Competition from new entrants
- Hospital procedure volumes and profitability progress